吡托鲁替尼治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。

IF 2.6 4区 医学 Q2 ONCOLOGY
Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Justin Taylor, Catherine C Coombs
{"title":"吡托鲁替尼治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。","authors":"Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Justin Taylor, Catherine C Coombs","doi":"10.1080/14796694.2025.2567834","DOIUrl":null,"url":null,"abstract":"<p><p>Pirtobrutinib, a novel noncovalent Bruton's tyrosine kinase (BTK) inhibitor (BTKi) has demonstrated significant potential in overcoming treatment resistance characterized by BTK mutations in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL). Unlike currently approved covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib that irreversibly bind to the cysteine 481 (C481) residue of BTK, pirtobrutinib's non-covalent binding enables it to maintain efficacy even in the presence of cysteine 481 serine (C481S) mutations which are the most common form of acquired resistance. This current review seeks to demonstrate the mechanism of action as well as the clinical efficacy of pirtobrutinib in treating patients with relapsed/refractory CLL/SLL and to describe ongoing studies of pirtobrutinib in combination with other agents and in earlier lines of therapy.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.\",\"authors\":\"Syed Ibrahim, Nghia Pham, Aarushi Sahni, Samantha Sekeres, Allison Cool, Justin Taylor, Catherine C Coombs\",\"doi\":\"10.1080/14796694.2025.2567834\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pirtobrutinib, a novel noncovalent Bruton's tyrosine kinase (BTK) inhibitor (BTKi) has demonstrated significant potential in overcoming treatment resistance characterized by BTK mutations in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL). Unlike currently approved covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib that irreversibly bind to the cysteine 481 (C481) residue of BTK, pirtobrutinib's non-covalent binding enables it to maintain efficacy even in the presence of cysteine 481 serine (C481S) mutations which are the most common form of acquired resistance. This current review seeks to demonstrate the mechanism of action as well as the clinical efficacy of pirtobrutinib in treating patients with relapsed/refractory CLL/SLL and to describe ongoing studies of pirtobrutinib in combination with other agents and in earlier lines of therapy.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2567834\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2567834","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Pirtobrutinib是一种新型的非共价布鲁顿酪氨酸激酶(BTK)抑制剂(BTKi),在克服慢性淋巴细胞白血病和小淋巴细胞白血病(CLL/SLL)中以BTK突变为特征的治疗耐药方面显示出显著的潜力。与目前批准的共价BTKi (cBTKi)如ibrutinib、acalabrutinib和zanubrutinib不可逆地结合BTK的半胱氨酸481 (C481)残基不同,pirtobrutinib的非共价结合使其即使在存在半胱氨酸481丝氨酸(C481S)突变(最常见的获得性耐药形式)的情况下也能保持疗效。本综述旨在证明吡托鲁替尼治疗复发/难治性CLL/SLL患者的作用机制和临床疗效,并描述正在进行的吡托鲁替尼与其他药物联合使用和早期治疗的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Pirtobrutinib, a novel noncovalent Bruton's tyrosine kinase (BTK) inhibitor (BTKi) has demonstrated significant potential in overcoming treatment resistance characterized by BTK mutations in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL). Unlike currently approved covalent BTKi (cBTKi) such as ibrutinib, acalabrutinib, and zanubrutinib that irreversibly bind to the cysteine 481 (C481) residue of BTK, pirtobrutinib's non-covalent binding enables it to maintain efficacy even in the presence of cysteine 481 serine (C481S) mutations which are the most common form of acquired resistance. This current review seeks to demonstrate the mechanism of action as well as the clinical efficacy of pirtobrutinib in treating patients with relapsed/refractory CLL/SLL and to describe ongoing studies of pirtobrutinib in combination with other agents and in earlier lines of therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信